Abviva, Inc. (AVVA.OB), a biomedical company that specializes in the development and commercialization of diagnostic and therapeutic products from mammastatin, a growth-regulatory protein that inhibits breast cancer cell growth, was recently noted as a stock to watch. Abviva’s research focuses on developing innovative breast cancer diagnostic and therapeutic products that can benefit individuals throughout the world.
Abviva’s growth strategy is to develop a fully integrated diagnostic and therapeutic business that is sustained by product and services revenues. Additionally, the company plans to commercialize the Mammastatin Serum Assay, which measures a woman’s risk of developing breast cancer, through its wholly owned subsidiary laboratory, as well as develop additional breast cancer therapies through internal and external collaborative research with pharmaceutical, biotechnology and research institutions.
The Mammastatin Serum Assay is currently being studied as a method of providing early detection of breast cancer in women who have no symptoms, and to identify women who are at increased risk of developing breast cancer. The company intends to continue to conduct research on mammastatin in order to advance the knowledge and understanding of the biological mechanisms underlying the mammastatin link to breast cancer. When detected early, women with breast cancer have up to a 98-percent probability of survival.
Let us hear your thoughts: Abviva, Inc. Message Board